^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iC9.GD2.CAR.IL-15 T-cells

    i
    Other names: iC9.GD2.CAR.IL-15 T-cells, autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes, autologous ic9-gd2car-cd28-cd3zeta-il-15-expressing T-cells, iC9-GD2. CAR.IL-15 T, Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch, CAR T-Cells Targeting the GD2 With IL-15+iCaspase9
    Associations

    News

    Trials
    Company:
    UNC Lineberger Comprehensive Cancer Center
    Drug class:
    IL-15R stimulant, GD2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2024 --> May 2025
    Trial primary completion date • CAR T-Cell Therapy
    |
    IL15 (Interleukin 15)
    |
    cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells
    over1year
    Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    IL15 (Interleukin 15)
    |
    iC9.GD2.CAR.IL-15 T-cells
    2years
    Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P1 trial • CAR T-Cell Therapy
    |
    IL15 (Interleukin 15)
    |
    iC9.GD2.CAR.IL-15 T-cells
    over2years
    Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Sep 2038 --> Jun 2039 | Trial primary completion date: Sep 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    IL15 (Interleukin 15)
    |
    cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells